Berman Capital Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Berman Capital Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$0	Buy	+13	New	+$583	﹤0.01%	2053

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Berman Capital Advisors's ARCT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Arcturus Therapeutics (ARCT) in Q3 2021: 13 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2053 among its holdings.

156 funds tracked by Wall St. Rank hold ARCT as of Q3 2021.

Berman Capital Advisors held 13 shares of Arcturus Therapeutics worth $0 as of Q3 2021.
Arcturus Therapeutics was a new Berman Capital Advisors position in Q3 2021.
Arcturus Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2053 holding.
156 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.